Zacks Research Has Optimistic Outlook of HALO Q1 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research boosted their Q1 2027 EPS estimates for shares of Halozyme Therapeutics in a research report issued on Monday, February 2nd. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $1.63 per share for the quarter, up from their prior estimate of $1.55. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. The firm had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period last year, the firm earned $1.27 EPS.

Several other brokerages have also commented on HALO. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Citizens Jmp increased their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research report on Monday, October 27th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $78.80.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $76.48 on Tuesday. The stock’s 50-day simple moving average is $69.01 and its two-hundred day simple moving average is $68.78. Halozyme Therapeutics has a twelve month low of $47.50 and a twelve month high of $79.50. The firm has a market capitalization of $8.99 billion, a P/E ratio of 16.10, a P/E/G ratio of 0.32 and a beta of 0.97. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 16,569 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the completion of the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $48,844,913.48. This represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 41,398 shares of company stock valued at $2,861,352 over the last three months. 2.90% of the stock is currently owned by insiders.

Institutional Trading of Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HALO. Root Financial Partners LLC purchased a new position in shares of Halozyme Therapeutics in the third quarter worth $25,000. Larson Financial Group LLC boosted its position in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the period. Richardson Financial Services Inc. boosted its position in Halozyme Therapeutics by 87.6% during the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 198 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Halozyme Therapeutics in the 2nd quarter worth $32,000. Finally, Employees Retirement System of Texas purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at about $34,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.